Prokaryotics Incorporated
Union, NJ
- UEI
- CBKMWXFE94Z4
- CAGE
- 7S6F5
- Primary NAICS
- 325411 Medicinal and Botanical Manufacturing
- SAM.gov registration
- Active through
Company facts
- Self-certified in SAM.gov
- Entity structure
- Corporate Entity (Not Tax Exempt)
- SAM.gov registration date
- Physical address
- 1000 Morris Ave, Union, NJ 07083, USA
- Website
- prokaryotics.com
- Founded
- 2017
- Employees
- 1-10
- Estimated annual revenue
- $0-$1M
- Industry
-
- Health Care
- Pharmaceuticals, Biotechnology & Life Sciences
- Pharmaceuticals
- SIC code
- 28 Chemical & Allied Products
- Profiles
Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .
Grant awards
Latest 5 listed here. See the rest on GovTribe.
Grant subawards
| Prime recipient | Prime award | Amount | Awarded |
|---|---|---|---|
| The Johns Hopkins University | U19AI189183 | $1,308,736 |
Similar vendors
About the company
Prokaryotics Incorporated is a pharmaceutical and biotechnology research company registered in the System for Award Management (SAM.gov), with its primary address located in Union, New Jersey. As a for-profit corporate entity, the company focuses on developing novel therapeutic approaches, specifically targeting challenging infectious disease challenges in the pharmaceutical research and development space. Their federal grant awards indicate a specialized focus on developing innovative antifungal and antibacterial agents with novel mechanisms of action, addressing critical unmet medical needs in treating drug-resistant pathogens.
The company has consistently received federal grant awards from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research federal grant program. Their research efforts have concentrated on developing mechanistically novel therapeutic interventions, including antifungal agents targeting cell wall biosynthesis pathways, glycosylphosphatidylinositol (GPI) biosynthesis inhibitors, and antibiotics targeting bacterial membrane and cellular processes. Specific research projects have included developing broad-spectrum antifungal agents effective against pathogens like Candida albicans, Candida auris, and Aspergillus fumigatus, as well as antibacterial compounds targeting Gram-negative bacteria like Carbapenem-resistant Enterobacteriaceae (CRE) and Acinetobacter baumannii. Their research aims to address expanding clinical resistance to standard-of-care therapeutics and reduce mortality rates associated with complex infectious diseases, with grant awards ranging from $170,000 to $299,697 and project periods typically spanning two to three years.
Quick answers
Is Prokaryotics Incorporated registered in SAM.gov?
Yes. Prokaryotics Incorporated's SAM.gov registration is active through August 19, 2027.
What is Prokaryotics Incorporated's CAGE code?
Prokaryotics Incorporated's CAGE code is 7S6F5, and its Unique Entity ID (UEI) is CBKMWXFE94Z4.
What is Prokaryotics Incorporated's most recent federal award?
Prokaryotics Incorporated's most recent federal grant award is Development of an active site inhibitor of FKS1 as a broad spectrum antifungal agent - we propose to develop a… (R44AI188848), from National Institute of Allergy and Infectious Diseases (NIH), on September 19, 2025.
On GovTribe
See Prokaryotics Incorporated's full federal record
- Federal grant awards
- Funding analysis by agency, NAICS and set-aside
- Similar vendors